文献速递儿科与产科急症重症综合管理与镇静镇痛

MIS-C 治疗:糖皮质激素单药对轻症是否足够?

MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases?
PubMed 文献 · Am J Emerg Med · 2024-06-27
一句话结论回顾性队列提示,无心脏受累的轻症 MIS-C 单用糖皮质激素可能是安全的治疗选择。

土耳其伊斯坦布尔一家三级医疗中心 2020 年 6 月 1 日至 2022 年 6 月 1 日的回顾性队列研究,纳入 97 例 MIS-C 患者,中位年龄 41(3–214)个月,56 例(57.7%)男性。全部患者入院时均有发热,体温 39 ℃(37.5 ℃–40.1 ℃);32 例(33%)超声心动图有心脏表现。65 例(67%)仅用糖皮质激素(Ⅰ组),32 例(33%)有严重表现和/或心脏受累者用糖皮质激素+静脉注射免疫球蛋白(Ⅱ组)。主要结局为临床恶化、休克、入住儿科重症监护病房及需额外免疫抑制药物;次要结局为 1 年随访时心血管和感染相关并发症。无死亡,1 年随访时所有患者无主诉、超声心动图均正常。作者认为,该研究提供初步证据:糖皮质激素单药对无心脏受累的轻症 MIS-C 是安全的替代治疗。

要点

  • 97 例 MIS-C 中 65 例(67%)仅用糖皮质激素、32 例(33%)用糖皮质激素+静脉注射免疫球蛋白,无死亡。
  • 32 例(33%)超声心动图有心脏表现:左心室功能障碍 13 例(13.5%)、冠状动脉受累 11 例(11.3%)、心腔扩张和/或心肌增厚 8 例(8.2%)。
  • 13 例(13.5%)需重症监护;66 例(68%)未用静脉注射免疫球蛋白。
  • 1 年随访时全部患者无主诉、超声心动图均正常。
  • 作者认为糖皮质激素单药对无心脏受累的轻症 MIS-C 是安全的替代治疗,属初步证据。

适用人群与场景

  • 2020 年 6 月 1 日至 2022 年 6 月 1 日土耳其伊斯坦布尔一家三级医疗中心收治的 MIS-C 患者,共 97 例,中位年龄 41(3–214)个月,56 例(57.7%)男性。
  • 按治疗分为仅用糖皮质激素组(Ⅰ组,65 例,67%)和糖皮质激素+静脉注射免疫球蛋白组(Ⅱ组,32 例,33%);后者为有严重表现和/或心脏受累者。

处置流程与药物剂量

  • 全部患者均接受糖皮质激素;仅用糖皮质激素者 65 例(67%),糖皮质激素+静脉注射免疫球蛋白者 32 例(33%,有严重表现和/或心脏受累)。

研究设计与关键结果

  • 回顾性队列研究,单家三级医疗中心,97 例 MIS-C 患者,中位年龄 41(3–214)个月,56 例(57.7%)男性。
  • 入院时全部患者有发热,体温 39 ℃(37.5 ℃–40.1 ℃);32 例(33%)超声心动图有心脏表现:左心室功能障碍 13 例(13.5%)、冠状动脉受累 11 例(11.3%)、心腔扩张和/或心肌增厚 8 例(8.2%)。
  • 13 例(13.5%)需重症监护;无死亡。
  • 主要结局为临床恶化、休克、入住儿科重症监护病房及需额外免疫抑制药物;次要结局为 1 年随访时心血管和感染相关并发症。
  • 1 年随访时全部患者无主诉,超声心动图均正常。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:作者称本研究提供的是初步证据。

对床旁实践的改变

  • 作者认为,糖皮质激素单药对无心脏受累的轻症 MIS-C 是安全的替代治疗,属初步证据;有严重表现和/或心脏受累者在本研究中接受了糖皮质激素+静脉注射免疫球蛋白。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effectiveness of using only glucocorticoids (GCs) in mild multisystem inflammatory syndrome (MIS-C) cases was compared with combined treatment [GCs + Intravenous immune globulin (IVIG)].

METHODS: This retrospective cohort study was conducted between June 1, 2020, and June 1, 2022, in a tertiary care center in Istanbul, Turkey. Clinical and investigational data of the MIS-C patients were analyzed. The patients were divided into two groups: those who received only GCs and those who received the GCs + IVIG combination. The primary outcome focused on assessing the deterioration of the patient's clinical condition, the occurrence of shock, admission to the pediatric intensive care unit (PICU), and the need for additional immunosuppressive medication. Secondary outcomes included evaluating the course of cardiovascular and infection-related complications observed at the one-year follow-up.

RESULTS: Ninety-seven MIS-C patients with a median age of 41 (3- 214) months were enrolled. Fifty-six (57.7%) patients were male. All the patients had fever at admission with a temperature of 39 °C (37.5 °C-40.1 °C). Thirty-two patients (33%) had cardiac findings on echocardiography [left ventricular dysfunction (n= 13, 13.5%), coronary artery involvement (n= 11, 11.3%), and dilation of cardiac cavities and/or increased cardiac muscle thickness (n= 8, 8.2%)]. Thirteen patients (13.5%) required intensive care. All patients received GCs [only GCs (group I; n= 65, 67%)], and 32 patients (33%) with severe manifestations and/or cardiac involvement received GCs + IVIG (group II). No mortality was observed. None of the patients had any complaints at the one-year follow-up, and all echocardiography findings were normal.

CONCLUSION: This study provides preliminary evidence that GC monotherapy is a safe treatment alternative for mild MIS-C cases without cardiac involvement.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Sütçü M, Kara EM, Yıldız F, et al. MIS-C Treatment: Is glucocorticoid monotherapy enough for mild cases? Am J Emerg Med. 2024. PMID: 39002497. doi:10.1016/j.ajem.2024.06.030

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。